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Dietary exposure to aﬂatoxins is one of the major risk factors for hepatocellular carcinoma. Individual susceptibility to
aﬂatoxin-induced hepatocarcinogenesis may be modulated by both genetic and environmental factors affecting metabolism. A
cross-sectional study was performed to evaluate determinants of the formation of aﬂatoxin covalently bound to albumin
(AFB1-albumin adducts). A total of 474 subjects who were free of liver cancer and cirrhosis and were initially selected as
controls for previous case–control studies of aﬂatoxin-induced hepatocarcinogenesis in Taiwan, were employed in this study.
Aﬂatoxin-albumin adducts were determined by competitive enzyme-linked immunosorbent assay, hepatitis B surface antigen
and antibodies to hepatitis C virus by enzyme immunoassay, as well as genotypes of glutathione S-transferase M1-1 and T1-1
by polymerase chain reaction. The detection rate of AFB1-albumin adducts was signiﬁcantly higher in males (42.5%) than in
females (21.6%) (multivariate-adjusted odds ratio=2.6, 95% conﬁdence interval=1.4–5.0). The formation of detectable
albumin adducts was moderately higher in hepatitis B surface antigen carriers (42.8%) than in non-carriers (36.6%)
(multivariate-adjusted odds ratio=1.4, 95% conﬁdence interval=1.0–2.1). In addition, the detection rate of AFB1-albumin
adducts tended to increase with the increasing number of null genotypes of glutathione S-transferase M1-1 and glutathione S-
transferase T1-1. In conclusion, this cross-sectional study has assessed the relative contributions of environmental exposure and
host susceptibility factors in the formation of AFB1-albumin adducts in a well characterised Chinese adult population. This
study further emphasises the necessity to reduce aﬂatoxin exposure in people living in an area endemic for chronic hepatitis B
virus infection.
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Pervious studies have indicated that hepatocellular carcinoma
(HCC) is of multifactorial origin with both viral and chemical
carcinogens involved in the multistage process. Although chronic
infection with hepatitis B virus (HBV) is now regarded as the
major cause of HCC in high-incidence areas (Yeh et al, 1989; Chen
et al, 1991; Ryder et al, 1992), ingestion of aﬂatoxin B1 (AFB1) has
also been implicated as another major contributor to risk (Yeh et
al, 1989; Ross et al, 1992; Wang et al, 1996a,b). Many studies have
conﬁrmed that parent compound AFB1 is converted to its carcino-
genic forms through metabolism by members of the endogenous
cytochrome P-450 enzyme superfamily to reactive 8,9-epoxide
metabolites, which can covalently interact with cellular DNA and
proteins (International Agency for Research on Cancer, 1992;
Gallagher et al, 1994; Guengerich et al, 1998). Among the major
epoxide-derived macromolecular adducts identiﬁed, the AFB1-albu-
min adduct correlates well with other aﬂatoxin measurements and
provides a cumulative measure of exposure over several months in
humans (Wild et al, 1986; Gan et al, 1988).
Accumulating evidence indicates that susceptibility to aﬂatoxin-
related HCC may be modulated by inter-individual differences in
metabolism (McGlynn et al, 1995; Chen et al, 1996b; Sun et al,
2001). Both epidemiological and experimental studies have demon-
strated a synergistic interaction between chronic HBV infection and
aﬂatoxin exposure in the development of HCC (Ross et al, 1992;
Wang et al, 1996a; Sylla et al, 1999). Taken together, the degree that
AFB1 contributes to risk of HCC may be inﬂuenced by both genetic
and environmental factors. Thus, we performed a cross-sectional
study of 474 control subjects enrolled in previous nested case–
control study of susceptibility to aﬂatoxin-related HCC (Wang et
al, 1996b; Sun et al, 2001) to evaluate the correlations of multiple
HCC enviromental and genetic susceptibility risk factors with the
formation of AFB1-albumin adducts in the peripheral blood.
MATERIALS AND METHODS
Study subjects
From July 1990 through June 1992, a community-based two-stage
liver cancer screening programme was carried out in seven town-
ships in Taiwan. The cohort characteristics and methods of
screening and follow-up have been described previously (Wang et
al, 1996b; Sun et al, 2001). Brieﬂy, in the two-stage screening
programme, study subjects aged 30 to 64 years were ﬁrst screened
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www.bjcancer.com(HBsAg), antibodies to hepatitis C virus (anti-HCV), alanine trans-
aminase (ALT), aspartate transaminase (AST), and a-fetoprotein
(AFP). HBsAg, anti-HCV, and AFP were tested by enzyme immu-
noassay using commercial kits (Abbott Laboratories, North
Chicago, IL, USA), while both ALT and AST levels were deter-
mined by serum chemistry autoanalyzer (Hitachi Model 736;
Hitachi Co., Tokyo, Japan) using commercial reagents (Biomer-
ieux, Mercy I’Etoile, France). Any subject who had a positive
status of HBsAg or anti-HCV, an elevated level of ALT (45 IU/
L), AST (40 IU L
71), or AFP (20 ng ml
71), or a family history
of HCC or liver cirrhosis among ﬁrst degree relatives was referred
for the second-stage screening by upper abdominal ultrasonogra-
phy. The abdominal ultrasonography was performed by board-
certiﬁed gastroenterologists who were well experienced in ultraso-
nographic examinations using Toshiba SAL-38B and SSA-240A
ultrasonographic apparatus with 3.75 MHZ real-time linear and
sector probes (Toshiba, Japan).
All participants were personally interviewed based on a struc-
tured questionnaire at recruitment. Blood samples were collected
from each study subject. Aliquots of serum, buffy coat, plasma,
and red blood cells were separated and stored at 7708C. Speci-
mens were transported in dry ice to the central laboratory at the
National Taiwan University and were kept in deep freezers until
examination. All study subjects gave informed consent for both
the interview and blood collection. In addition, anonymity of study
subjects was maintained by the numerical coding of questionnaires
and blood samples. This community-based cancer screening project
was supported and approved by Department of Health, Executive
Yuan.
The present study is concerned with 474 subjects who were initi-
ally selected as controls for previous nested case–control studies of
aﬂatoxin-related hepatocarcinogenesis (Wang et al, 1996b; Sun et
al, 2001). These individuals were not affected with HCC or cirrho-
sis through follow-up period. In fact, data used in the present
study were obtained by mining of the original data set from these
previous nested case-control studies.
AFB1-albumin adducts in serum
An enzyme-linked immunosorbent assay was used to determine the
level of AFB1-albumin adducts in serum as previously described
(Wang et al, 1996a; Sun et al, 2001). This assay had 50% inhibition
of antiserum binding at 10–20 fmol AFB1 adduct per well. The
limit of sensitivity (20% inhibition) when assaying the equivalent
of 200 mg albumin per well was 0.01 fmol mg
-1. Samples were
assayed by duplicate analysis in duplicate wells. Samples with
520% inhibition were considered non-detectable. Two control
samples were analysed with each batch of sera, a pooled sample
of plasma from non-smoking US subjects and a positive control
of serum from a rat treated with 1.5 mg AFB1.
GSTM1-1 and GSTT1-1 genotypes
GSTM1-1 genotyping for gene deletion was performed by PCR
ampliﬁcation with primers for exons 6 and 7, which produced a
210 bp band, according to the method of Bell et al (1993).
GSTT1-1 genotype was determined using the technique of Pemble
et al (1994), with the modiﬁcation that b-globin primers were
added to the PCR.
Statistical methods
Because it was not considered appropriate to assign a value to the
undetectable serum level of AFB1-albumin adducts, the adducts
level was analysed as a binary rather than continuous variable.
Odds ratios (OR) and their 95% conﬁdence intervals (CI), which
were derived from logistic regression models, were used to indicate
the magnitude of the associations between formation of AFB1-albu-
min adducts and various variables. In addition, months of year for
blood sample collection were grouped into four seasons in order to
evaluate seasonal variations in the detectable levels of AFB1-albu-
min adducts. All analyses were performed with SAS software
(SAS Institute, Cary, NC, USA) and all P values for tests of statis-
tical signiﬁcance were based on two-tailed probability.
RESULTS
The demographic data concerning the study subjects and the rela-
tionship of the positivity of AFB1-albumin adducts with these
demographic characteristics are described in Table 1. There were
no signiﬁcant variation in detection rate of AFB1-albumin adducts
among study townships (ranging from 33.3 to 47.5%), seasonality
of sample collection (ranging from 36.8 to 43.0%) and age groups
(ranging from 26.9 to 40.6%). In contrast, males had signiﬁcantly
higher detection rate of AFB1-albumin adducts than females (42.5
vs 21.6%) with an odds ratio (OR) of 2.7 (95% CI=1.5–5.0).
Results with regard to the detection rate of AFB1-albumin
adducts in relation to multiple HCC risk factors are summarised
in Table 2. AFB1-albumin adducts were detectable in 42.8% (86
of 201) of HBsAg carriers and 36.6% (100 of 273) of HBsAg
non-carriers. The difference in the detection rate was moderately
signiﬁcant between the two groups (OR=1.3, 95% CI=1.0–1.9).
This detection rate was higher in study subjects who smoked cigar-
ettes (43.8%) than in those who never smoked cigarettes (35.1%),
with a moderately signiﬁcant OR of 1.4 (95% CI=1.0–2.1). In
addition, there were also moderately signiﬁcant differences in the
adduct detection rate depending on GSTM1-1 and GSTT1-1 geno-
types; the detection rate was higher in individuals with either
GSTM1-1 null (43.0%) or GSTT1-1 null (44.2%) genotype than
in those with GSTM1-1 (36.4%) or GSTT1-1 (35.9%) present.
The OR of detectable AFB1-albumin adducts associated with
GSTM1-1 or GSTT1-1 null genotype was 1.3 (95% CI=1.0–1.9)
and 1.4 (95% CI=1.0–2.0), respectively. On the other hand, the
detection rate was lower in anti-HCV-positive subjects (30.6%)
than negative subjects (41.6%) (OR=0.7, 95% CI=0.3–1.3). There
was again a slightly lower detection rate in individuals who
consumed alcohol (36.2%) than in those who never drank alcohol
(39.9%).
The effect of a combination of GSTM1-1 and GSTT1-1 geno-
types on the detectable adduct levels was then analysed and
stratiﬁed by HBsAg status. In this case the positivity of AFB1-albu-
min adducts tended to increase with increasing number of the null
genotype of GSTM1-1 and GSTT1-1 in both the HBsAg carrier and
non-carrier groups, albeit the trend was statistically non-signiﬁcant
(Table 3).
Results of logistic regression analysis of multiple factors asso-
ciated with the positivity of AFB1-albumin adducts are shown in
Table 4. After multivariate adjustment, male gender and positive
HBsAg status was still signiﬁcantly associated with positivity of
AFB1-albumin adducts (for males: adjusted OR=2.6, 95%
CI=1.4–5.0; for HBsAg carriers: adjusted OR=1.4, 95% CI=1.0–
2.1). Whereas, no signiﬁcant association with detectable AFB1-
albumin adduct levels was observed for age, anti-HCV positive
status, habits of cigarette smoking and alcohol intake, and the null
genotype of GSTM1-1 and GSTT1-1.
DISCUSSION
Data from human epidemiological studies have demonstrated that
exposure to AFB1 is one of the major risk factors in the multifac-
torial etiology of HCC (Ross et al, 1992; McGlynn et al, 1995; Chen
et al, 1996a,b; Wang et al, 1996b; Sun et al, 2001). Many studies
have further conﬁrmed that the toxic and carcinogenic effects of
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gerich et al, 1992; Gallagher et al, 1994). Based upon knowledge
of AFB1 metabolism, a number of molecular dosimetry markers
of aﬂatoxin exposure have been developed (Gan et al, 1988; Groop-
man et al, 1992; Yu et al, 1997). Among them the AFB1-albumin
adduct has been a useful biomarker reﬂecting long-term exposure
to aﬂatoxins in different populations (Gan et al, 1988; Wild et
al, 1990) and linking to an elevated risk of HCC (Chen et al,
1996a,b; Wang et al, 1996b; Sun et al, 2001). Thus, exploring the
determinants of formation of AFB1-albumin adducts may contri-
bute to understanding the complex interaction among multiple
risk factors involved in hepatocarcinogenesis.
The major factors determining the formation of AFB1-albumin
adducts for an individual in this population are gender and HBsAg
carrier status. Males have signiﬁcantly higher detectable adduct
levels than females. This ﬁnding is in contrast to those observed
in previous studies whether there was no signiﬁcant association
between gender and aﬂatoxin adduct levels (Wang et al, 1996a;
Wild et al, 2000). The gender difference in detectable adduct levels
might be attributable to differences in aﬂatoxin exposure or meta-
bolism. It has been noted that HCC is 2–3 times more frequent in
males than in females in Taiwan, despite their similarity in HBsAg
carrier status (Chen et al, 1997). The gender difference in the
formation of AFB1-albumin adducts might contribute to the
increased susceptibility to hepatocarcinogenesis in males.
In this study, there was moderately signiﬁcant effect of HBsAg
carrier status on detectable AFB1-albumin adduct levels. HBsAg-
positive adults have higher detectable adduct levels than HBsAg-
negative adults (42.8 vs 36.6%). In particular, HBsAg-positive
males have 50% higher frequency of detectable adducts than their
HBsAg-negative counterpart (46.7 vs 39.5%; adjusted OR=1.5, 95%
CI=1.1–2.4; data not shown). The possible association between
chronic HBV infection and the increased activation of AFB1 has
been examined in epidemiological studies. Two studies of young
Gambian children have reported higher AFB1-albumin adduct













Table 1 Baseline characteristics of study subjects and in relation to the
detection rate of AFB1-albumin adducts
AFB1-albumin adducts
Detection rate Odds ratio
Variable Group No. (%) (95% CI
a)
Sex Female 74 21.6 1.0
Male 400 42.5 2.7 (1.5–5.0)
Age 30–39 26 26.9 1.0
40–49 102 40.2 1.8 (0.7–4.7)
50–59 251 40.6 1.9 (0.8–4.6)
60–64 95 37.9 1.7 (0.6–4.3)
Residence Sanchi 24 33.3 1.0
Chutung 70 44.3 1.2 (0.7–2.2)
Potzu 59 47.5 1.4 (0.7–2.6)
Kaohsu 36 41.7 1.1 (0.5–2.3)
Makung 132 34.2 0.8 (0.5–1.3)
Huhsi 49 34.7 0.8 (0.4–1.6)
Paihsa 84 41.7 1.3 (0.9–1.9)
Time of collection March–May 190 36.8 1.0
(months of year) June–August 104 38.5 1.1 (0.7–1.8)
September–November 101 41.6 1.2 (0.7–2.0)
December–February 79 43.0 1.3 (0.8–2.2)
aConﬁdence interval.
Table 2 Associations between the detection rate of AFB1-albumin ad-
ducts and infection with hepatitis B and C viruses, habits of cigarette smok-




Factors Group No. rate (%) (95% CI
a)
HBsAg
a Negative 273 36.6 1.0
Positive 201 42.8 1.3 (1.0–1.9)
Anti-HCV
a Negative 406 41.6 1.0
Positive 36 30.6 0.7 (0.3–1.3)
Cigarette smoking Non-smoker 248 35.1 1.0
Smoker 226 43.8 1.4 (1.0–2.1)
Alcohol drinking Non-drinker 394 39.9 1.0
Drinker 80 36.2 0.9 (0.5–1.4)
GSTM1-1 Non-null 209 36.4 1.0
Null 193 43.0 1.3 (1.0–1.9)
GSTT1-1 Non-null 234 35.9 1.0
Null 163 44.2 1.4 (1.0–2.0)
aHBsAg, hepatitis B surface antigen, anti-HCV, antibodies to hepatitis C virus; CI,
conﬁdence interval.
Table 3 The detection rate of AFB1-albumin adducts in relation to com-
bined genotypes of glutathione S-transferase (GST) M1-1 and T1-1 by he-
patitis B carrier status
HBsAg
a
carrier Detection Odds ratio
status GSTM1-1/T1-1 No. rate (%) (95% CI
a)
Non-carrier Both non-null 59 30.5 1.0
At least one null 118 36.4 1.2 (0.7–2.1)
Both null 49 46.9 1.8 (0.9–3.8)
Test for trend P=0.142
Carrier Both non-null 66 36.4 1.0
At least one null 72 44.4 1.3 (0.7–2.3)
Both null 31 51.6 1.7 (0.7–3.4)
Test for trend P=0.084
aHBsAg, hepatitis B surface antigen; CI, conﬁdence interval.
Table 4 Logistic regression analysis of multiple factors associated with
the detection rate of AFB1-albumin adducts












Cigarette smoking Non-smoker 1.0
Smoker 1.2 (0.8–1.8)








aConsecutive scores of 1, 2, 3, and 4 were assigned to age groups of 30–39, 40–49,
50–59, and 60–64 years, respectively.
bHBsAg, hepatitis B surface antigen; anti-
HCV, antibodies to hepatitis C virus; GSTM1-1, glutathione S-transferase M1-1;
GSTT1-1, glutathione S-transferase T1-1; CI, conﬁdence interval.
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found a higher AFB1-albumin adduct levels in HBsAg-positive than
negative subjects (Chen et al, 2001). Whereas, results from studies
in adults are somewhat contradictory; in Guinea there was a non-
signiﬁcant increase in AFB1-albumin adducts in HBsAg-positive
individuals (Diallo et al, 1995), while in China (Wang et al,
1996a) and Gambia (Wild et al, 2000) no such effect was observed.
Furthermore, two recent studies of Chinese adult populations
revealed that HBsAg positive status did not have signiﬁcant effects
on the temporal variability in AFB1-albumin adducts (Wang et al,
1996a; Ahsan et al, 2001). Therefore, we are left with apparent
inconclusive results between studies in children and adults as well
as between studies in adults in different populations regarding the
effect of chronic HBV infection on AFB1-albumin adduct levels. In
this study, a moderately signiﬁcant difference in detectable AFB1-
albumin adduct levels was found between HBsAg-positive and
negative adults, particularly in males. This ﬁnding may result in
part from the selection of study subjects from individuals who
participated in a liver cancer screening programme. Those subjects
may have viral-associated underlying subclinical liver diseases and
may have a signiﬁcant stimulation of the activation of AFB1,a s
indicated in previous studies (de Flora et al, 1985). Although it
is known from experimental studies that liver injury associated
with HBV can affect expression of carcinogen metabolizing
enzymes (de Flora et al, 1989; Chemin et al, 1999), the biological
mechanism that underlies the interaction between chronic HBV
infection and increased activation of AFB1 in humans merit further
studies.
Accumulating evidence indicates that genetic polymorphisms in
AFB1 metabolising enzymes are a factor in individual susceptibility
to aﬂatoxin-induced hepatocarcinogenesis (McGlynn et al, 1995;
Chen et al, 1996b; Sun et al, 2001). Members of the glutathione
S-transferase (GST) family, such as GST-m (GSTM1-1) and GST-
y (GSTT1-1), are important candidates for involvement in suscept-
ibility to aﬂatoxin-related liver cancer because they may regulate an
individual’s ability to metabolize the ultimate carcinogen of aﬂa-
toxins, the exo-epoxide (Johnson et al, 1997). The current study
observed that the detection rate of AFB1-albumin adducts tended
to increase as the number of null genotypes of GSTM1-1 and
GSTT1-1 increased. This biological gradient was observed in both
HBsAg carriers and non-carriers, albeit the trend was statistically
non-signiﬁcant.
In essence, our knowledge base about determinants of formation
of AFB1 macromolecular adducts in humans is still limited. In this
study, we have assessed the relative contributions of environmental
determinants and host susceptibility factors in the formation of
aﬂatoxin–albumin adducts in a well characterised Chinese adult
population. The result of present study suggests that gender and
HBsAg carrier status are major determinants of the formation of
aﬂatoxin covalently bound to albumin. This study further empha-
sises the necessity to reduce aﬂatoxin exposure in people living in
an area endemic for chronic HBV infection.
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